Orthotw iconOrthotwSep 16, 2026 ~6 min source read

Treace to Present New Foot & Ankle Devices and 2- to 5-Year Clinical Data at AOFAS 2026

Treace Medical will showcase next-generation instrumentation, minimally invasive systems, implants, software, biologics and multicenter clinical-study results at the AOFAS Annual Meeting in Seattle, Sept. 16–19, 2026.

Treace Highlights Product Innovations and Clinical Data Across its Expanding Foot & Ankle Portfolio at the 2026 AOFAS Annual Meeting

Share this story

Send the public story page.

Useful takeaways from this story.

Treace will feature new devices across 3D bunion correction, midfoot and hindfoot fusion, and minimally invasive procedures at AOFAS 2026.

Three multicenter clinical data presentations include 5-year ALIGN3D Lapiplasty results, 2-year MTA3D Adductoplasty interim results, and an observational SPRINT SpeedPlate study.

New product highlights include Lapiplasty Lightning System, Tailorplasty MIS Tailor’s Bunion System, Treace X-ray App, HyperPlate XM, SuperBite screws, CartiBlaster instruments, and VitaFuse graft.

# What Treace is showing at AOFAS 2026

# Product categories and specific technologies

  • Lapiplasty Lightning System: next-generation instrumentation paired with the SpeedTMT implant family. The system is described as designed to give surgeons control of triplanar correction and to reduce surgical steps for faster procedures.
  • Tailorplasty MIS Tailor's Bunion System: a minimally invasive solution for tailor's bunions (bunionettes), addressing deformities of the 5th metatarsal estimated to affect roughly 5–10% of adults.
  • SuperBite Fully-Threaded Compression Screws: self-drilling, comprehensive screw system intended to reduce steps and save time in fusion and osteotomy procedures across the forefoot, midfoot and hindfoot.
  • HyperPlate XM Dynamic Compression Locking Implant: fixation construct combining locking screws with dynamic compression, shaped anatomically for fusion in larger midfoot and hindfoot bones.
  • CartiBlaster Powered Joint Prep instruments: sterile, single-use tools for cartilage removal and joint preparation in fusion procedures for midfoot and hindfoot joints.
  • VitaFuse Bioactive Glass Graft: synthetic bone graft added to Treace's biologics line, joining CortiFuse tissue-based graft and procedure-specific wedges.

# Clinical data being presented

  • ALIGN3D Lapiplasty: A five-year analysis of a prospective multicenter study on triplanar tarsometatarsal arthrodesis with early weightbearing, covering radiographic, clinical and patient-reported outcomes. Presentation scheduled Friday, Sept. 18 at 8:45 a.m. PST by Daniel Farber, MD (Lehigh Valley Orthopedic Institute).
  • MTA3D Adductoplasty: Two-year interim, multicenter prospective results reporting radiographic and patient-reported outcomes for combined metatarsus adductus and hallux valgus correction with early weightbearing. Presentation scheduled Thursday, Sept. 17 at 4:00 p.m. PST by Mark Easley, MD (Duke University).
  • SPRINT SpeedPlate observational study: Audio poster covering radiographic and patient-reported outcomes following joint arthrodesis in the foot using a novel dynamic compression implant system, presented by Jody McAleer, DPM (Jefferson City Medical Group).

# What this means for surgeons and procedures

Treace is positioning a set of interoperable tools: updated instrumentation and implants for 3D bunion correction, MIS options for fifth-metatarsal deformities, imaging software for workflow support, and hardware plus biologics aimed at fusion procedures beyond the forefoot. The clinical presentations provide medium- and longer-term outcome data for surgeons considering these techniques and implants.

# Logistics and presentation timing

Treace will host surgeon training events and staff an exhibit booth during the AOFAS meeting. The three scheduled data presentations provide specific time slots for clinicians to review 2- and 5-year outcomes and an observational series on a dynamic compression implant.

# Bottom line

Treace's AOFAS program combines product launches that broaden its procedural reach with clinical data intended to inform adoption decisions for Lapiplasty-derived techniques and newer mid/hindfoot fixation and biologic options.

More context around this story.

Loading more related stories...

Keep reading in the app

Open the app view to save this story, compare related coverage, and continue from the same source.

Open in app